eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
Clinical research

Late to early velocity index as a predictor of iatrogenic femoral artery pseudoaneurysm recurrence in patients treated with ultrasound-guided thrombin injection

Jacek Kurzawski
Agnieszka Janion-Sadowska
Łukasz Zandecki
Marianna Janion
Marcin Sadowski

Department of Cardiology, Świętokrzyskie Cardiology Centre, Kielce, Poland
Institute of Medical Sciences, Jan Kochanowski University, Kielce, Poland
Online publish date: 2019/05/21
Article file
- Late to early.pdf  [0.52 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


A pseudoaneurysm (psA) develops as a consequence of arterial wall rupture or injury. It complicates up to 8% of interventional cardiovascular procedures [1–4]. Ultrasound-guided thrombin injection (UGTI) is currently the first-line treatment for patients with psA, with a success rate exceeding 94% [1, 3–12]. The remaining patients are referred for surgical repair or stent graft implantation, or are rarely treated with coil embolization or various other substances [2, 4, 13–20]. The main objective of UGTI is to promote thrombus formation within the psA lumen, ceasing blood leakage from the arterial lumen, and thus the occlusion (embolization) of the psA. It is estimated that recurrence may follow obliteration using UGTI in 2.5% to 13% of psA patients. As a result, in cases where a repeat procedure is warranted, complications can occur which are due to prolonged hospitalization and thrombin treatment, which is a very potent pharmacological agent [3, 4, 10, 11].
Moreover, there still exists some ambiguity on the recommended dosage of thrombin, and its therapeutic range. It is also unknown which patients are most at risk for psA recurrence. Significant results from the literature are summarized in Table I. The objective of the present study was to define predictors of psA recurrence after UGTI treatment.

Material and methods

From June 2004 to January 2017 a total of 46,181 patients with transcatheter cardiovascular interventions (i.e. coronary angiography and angioplasty, electrophysiological examination and ablation, peripheral angiography, intra-aortic balloon pump insertion) underwent a prospective ultrasound screening for the presence of transfemoral access site-related complications. In 515 (1.1%) cases femoral artery psA was confirmed. Of these, 508 (98.6%) underwent UGTI, 3 (0.6%) were referred to vascular surgery, 2 (0.4%) had a spontaneous psA thrombosis, and in 1 (0.2%) patient an effective ultrasound-guided compression was performed. psAs were detected using the following devices: Hewlett-Packard Sonos 2000, Sequoia C256, Sequoia C512 and General Electric Vivid E9 with linear 7–10 MHz and sector 2.5–3.5 MHz probes. Data were acquired using two-dimensional imaging and color-Doppler mapping. Blood flow across the psA neck was assessed using pulse-wave and continuous-wave spectral Doppler. A definitive diagnosis was made after visualization of the neck and/or communicating channel, as well as a cavity or cavities with at least one current inflow (Figures 1 A, B). The following qualitative and quantitative parameters (considered as independent variables) were analyzed: age, sex, type of cannulated vessel (i.e. artery or vein) and the exact cannula location (i.e. common, superficial or deep femoral artery), sheath size, hemostatic agents, inpatient versus outpatient diagnostic setting, the time interval of vessel puncture to UGTI treatment, the number and volume of psA cavities, the length of the communicating channel, the number of UGTI attempts, the thrombin dose given during the first UGTI range (i.e. < 200 IU, 200–600 IU, > 600 IU), as well as total thrombin doses per patient. Theoretical psA volume was obtained by using the volume of an ellipsoid formula 4/3(a × b × c); where a, b and c are radii along each axis. A repeat ultrasonography was performed 1–3 days after the initial test and at 7 days following UGTI. UGTI-related complications were assessed as previously described [11].
The effectiveness of UGTI treatment was confirmed by a thrombus in the entire psA chamber, visible also with no inflow towards the psA (either in the communicating channel or in the chamber itself), which was detected by color or pulsed-wave Doppler. The outflow Doppler spectrum during diastole, between two consecutive systolic inflow phases, together with late to early velocity index (LEVI, a newly proposed parameter) in the outflow spectrum, was also analyzed (Figure 2). The primary endpoint was psA recurrence following the initial UGTI and was defined as any inflow toward the psA (either in the communicating channel or in the chamber itself) detectable by color or pulsed-wave Doppler. The study population was subdivided into two groups. The UGTI = 1 group consisted of patients with only one UGTI attempt and no evidence of a psA recurrence. The UGTI > 1 group consisted of patients with a psA recurrence and in which the UGTI treatment was repeated until complete psA obliteration was achieved. There were no specific exclusion criteria. Written informed consent for UGTI was obtained from all patients prior to the treatment. The study was approved by the Bioethics Committee of the local chamber of physicians.

Thrombin injection under the guidance of ultrasound

The procedure was performed using bovine thrombin (“Thrombin 400” and “BioThrombin 400”, Biomed, Wytwórnia Surowic i Szczepionek, Lublin, Poland). It is produced as a sterile powder (one 2 ml vial contains 400 IU) and a solvent (another 2-ml vial with 0.9% NaCl solution). A 1 ml syringe and needles of either 21G (0.8 × 40 mm) or 22G (90 mm) were used in the procedure. After the treatment, UGTI patients were kept on bed rest for 16–25 h, with follow-up ultrasonography at 24–72 h, and at 7 days following the procedure. In patients with psA recurrence a subsequent UGTI was performed. The procedure was repeated until complete psA obliteration.

Statistical analysis

The distribution of the continuous variables was analyzed for normality using the Shapiro-Wilk test. As most of these variables had non-normal distribution, data are shown as median, lower and upper quartiles (Q1–Q3), and minimum and maximum values. The groups were compared using the non-parametric Mann-Whitney U test (unpaired), or the Wilcoxon signed rank test (paired), or Kruskal-Wallis test (more than two unpaired groups) with post-hoc analysis. Categorical variables are presented as percentages and numbers. The groups were compared for two categorical variables using the chi-square test or Fisher’s exact test when it was required. Receiver operating characteristic (ROC) analysis was used to obtain a good predictor for UGTI. The area under the curve (AUC), with odds ratio (OR) and 95% confidence intervals (CI) and a ROC curve plot, were presented. A p < 0.05 for two tailed tests was considered significant. All calculations were performed using SPSS Statistics v. 23 and R (version 3.1.2, IBM, USA).



There were no differences in age, sex, body mass index, body surface area, arterial hypertension, and presence of diabetes or dyslipidemia between the groups. Of note, heart failure was significantly more frequent in the UGTI > 1 group. In 486 (95.7%) patients the common femoral artery or its branches (common 64%, superficial 32%, deep 4%) was identified as the cannulation site, while it was found that in 22 (4.3%) patients the femoral vein (due to inadvertent catheter placement) was the cannulation site (Table II).

Thrombin injection and complications

Complete psA embolization after the initial procedure occurred in 432 (85%) patients. In 76 (15%) patients, a single repeat thrombin injection was necessary for complete treatment. However, 2 injections in 49 patients (64%), 3 in 15 patients (20%), and 4 or more in 12 patients (16%) were required for total ablation. During the first UGTI attempt a thrombin dose < 200 IU was sufficient in both subgroups (UGTI = 1, UGTI > 1), whereas doses > 600 IU were most frequent in subsequent treatments in the UGTI > 1 group. The total thrombin dose was also lower in the UGTI = 1 group. In the UGTI > 1 group the first procedure required larger doses of thrombin when compared with the single-procedure group UGTI = 1, and further attempts in UGTI > 1 were also associated with higher thrombin doses as compared to the first procedure in this group (Figure 3 A). During UGTI in 71 (14%) patients, there was an unintentional thrombin leakage from the psA to the vascular lumen resulting in transient paresthesia, numbness, tingling or mild pain. This complication was more common in the UGTI > 1 group. There was one pulmonary embolism in the UGTI = 1 group. In this case, the psA coexisted with an arterio-venous fistula, resulting in the thrombin leakage out of the psA to the femoral vein (Table II). The antiplatelet and anticoagulant medications, in different combinations, were similar in both groups (Table III), and were not associated with the number of UGTI attempts in the UGTI > 1 group.

The recurrent pseudoaneurysm characteristics

The psA recurrence was more common in patients with a psA volume exceeding 5 mL and a short communicating channel. A LEVI of < 0.2 discriminated between the UGTI = 1 and UGTI > 1 groups, and was observed more frequently in patients with a time interval from the vessel puncture to UGTI exceeding 7 days. In addition, LEVI (AUC = 0.997, 95% CI: 0.952–1; 95% CI: 0–0.84) and the time interval between vessel puncture and UGTI were the best predictors for psA recurrence (Figures 3 B, D). The psA recurrence was more common if the time from vessel cannulation to UGTI exceeded 7 days (Figure 3 D).


Seven large studies have reported on the results of UGTI treatment, each of them documenting therapy outcomes in over 100 patients with psA [1, 3, 4, 9–12]. The rate of recanalization has been estimated at 5 to 13%; however, the potential causes have not been investigated or discussed sufficiently (Table I). In our study, after performing more than 500 UGTI treatments, complications were detected in a larger proportion of the total patients (15.6%). The primary finding of our study is the identification of parameters which predict which patients are at risk for recurrent psA after UGTI. This information is of great clinical importance, as thrombin is a very potent agent with a series of dangerous complications, especially when used in repeated UGTI treatments.

Concomitant medication

Antiplatelet and anticoagulant therapy remains a gold standard in many transcatheter cardiovascular procedures. In the present study, half of the patients received dual antiplatelet therapies (i.e. aspirin + clopidogrel) and 23% received a combination of three antiplatelet or anticoagulant drugs (i.e. aspirin, clopidogrel or ticlopidine, unfractionated heparin, low molecular weight heparin, vitamin K antagonist). Other studies have not documented any significant effect of these medications on UGTI treatment success [4, 5, 10, 11]. Our findings show that these drugs were not predictive of psA recurrence (Table III). Unfortunately, none of the previous investigations evaluated UGTI success in patients receiving a non-vitamin K antagonist oral anticoagulant (NOAC). Although there are currently no reports available, it appears reasonable to switch from dabigatran to a different NOAC prior to UGTI, as dabigatran acts as a thrombin inhibitor and may attenuate the effect of UGTI.

Morphology of pseudoaneurysm

There are several structural types of pseudoaneurysms. Most frequently, they are divided into unilobed and multilobed, with a communicating channel or an opening between the psA cavity and the affected artery [3, 4, 9–11]. Unfortunately, the psA morphology has not been discussed in detail in patients with recanalization. Our study shows that the failure of primary UGTI treatment is likely related to a psA volume exceeding 5 ml (p = 0.032). It is possible that primary injection of thrombin into a distal psA cavity (recommended in multilobed psA) prevents an adequate amount of thrombin from entering the proximal cavity. As such, the thrombus formations may be less stable than in the distal cavity. Conversely, in a psA with a large single cavity, thrombin is generally injected as far as possible away from the neck, resulting in this region having low clot stability as well.

Time interval from pseudoaneurysm formation to thrombin injection

When UGTI is performed a substantial time period after the initial artery puncture, there is often a need for repeat or multiple UGTI treatments [4, 11]. In our study, a delay in UGTI initiation greater than 7 days was a significant risk factor for psA recurrence. While direct evidence remains elusive, we hypothesize that a long delay in the diagnosis of a psA may cause morphological remodeling of the inner lining of the psA cavity and false channel. As a result, this could have a negative effect on clot stabilization. To the best of our knowledge, no previous study has reported data on the consequences of the time period between the vessel puncture and UGTI. As such, our study is the first to suggest this potentially important finding, which could impact future patient care.

Thrombin dose

In the largest studies previously conducted, the average combined thrombin dose during UGTI ranged from 200 to 450 IU [1, 3, 4, 9–11]. Despite different modalities of thrombin application, an average single bolus of 100 IU of thrombin at a time was injected in these previous studies. In our study we achieved a UGTI success rate of 97% with a lower average total thrombin dose of 150 IU. In patients with psA recurrence, significantly more thrombin was required in the second UGTI treatment. Furthermore, the amount of thrombin used during the first procedure in the UGTI > 1 group was significantly higher when compared to the single procedure in the UGTI = 1 group. This could potentially increase the risk of thrombin leak towards the arterial lumen. Other investigators have not provided sufficient data on the thrombin dose used in the repeated UGTI, and as such our findings are the first to present these data.

Spectral Doppler waveform analysis

Following a precise analysis of the spectral Doppler waveform, we hypothesize that early and late velocities are not arranged randomly. The relationship between these velocities has not been studied previously. Therefore, we proposed the LEVI as a novel parameter for psA recurrence risk assessment. We observed that LEVI depended on the psA cavity size, or the stage of clot formation and retraction. A normal arterial Doppler spectrum is three-phasic (Figure 2 A). It appears that most frequently the early outflow velocity is greater than the late velocity, and therefore LEVI is less than 1.0 (Figure 2 B). In the case of psA, “the wall” seems to be a simplification, as the newly developed psA has no true, unique wall; it is limited by the surrounding tissues as well as a flaccid fresh thrombus adhering to the peripheral borders. We observed that this is particularly valid if the psA is diagnosed early (e.g. less than 7 day after the index procedure). A rigid wall is often present in an older psA (existing far longer than 7 days). The high early outflow velocity is a result of the compliant nature of the parietal thrombus, as well as the soft tissues surrounding the psA.
Elasticity propels the largest amount of blood at the beginning of outflow, then the flow decreases until the beginning of the next inflow. In contrast, during UGTI, when the psA cavity is partially filled with a fresh thrombus, its compression at the early beginning of outflow results in a flat spectral Doppler waveform and LEVI equals 1.0 (Figure 2 C). When the psA cavity is large, LEVI may be even greater than 1.0. We hypothesize that the parietal thrombus might be responsible for this specific pattern, as at the beginning of outflow the thrombus compression absorbs energy, and the velocity is lower than at the end of this phase (Figures 1 B, 2 D). In our study, patients with the psA recurrence after UGTI had a flow velocity that was very low in the late outflow phase when compared to the initial value. A LEVI of less than 0.2 was a significant predictor of a psA recurrence. In subjects with a late diagnosis of psA, the spectral Doppler waveform seems to be atypical, as it is very short and steep and may mimic arterial blood flow, but at higher velocities and without the third phase (Figure 2 F). In such patients LEVI equals 0, because no blood flow is recorded at the end of outflow, prior to the next cycle.

Iatrogenic immunization after UGTI

Administration of a heterologous substance, such as bovine thrombin, during UGTI may cause iatrogenic immunization. Exposure to thrombin during a second procedure may potentiate these immune responses [21]. In our study, none of the patients, despite multiple UGTI attempts, developed an immunization reaction. This was most likely due to the application of thrombin in short intervals. Indeed, more than four UGTI attempts were made within 5 days in some cases. It was possible this occurred because the patients had not had exposure to bovine thrombin previously. Some investigators have previously demonstrated that such reactions can range from mild clinical symptoms, such as fever, hypotension, bradycardia or urticaria, to full anaphylaxis [3, 22, 23]. Multiple attempts at UGTI treatment have already been reported, but without specifying the safe time interval for repeat thrombin injection [4, 9, 10]. Although no specific data are available, we hypothesize that it would be reasonable to choose human thrombin in patients previously exposed to a bovine treatment.

Complications of UGTI

Potential complications of thrombin injection were clearly described in a review paper by Webber et al. [17], and in a small sample of 50 subjects by Krueger et al. [5]. Evidence from large studies indicates that UGTI rarely causes serious complications, such as arterial or pulmonary embolism [3, 4, 10–12, 17, 18, 24, 25]. However, mild complications can result from unintentional thrombin leak from the psA cavity towards the native circulation, as a delay of 3 to 90 s (15 s on average) between thrombin injection and thrombus formation has been reported [4, 9, 11]. When this occurs, transient paresthesia, numbness, tingling or mild pain can be observed; however, they resolve within minutes due to native fibrinolytic activity. Paresthesia during UGTI was previously detected in several studies, but no in-depth analysis of the event has been performed [4, 9]. However, it has previously been suggested to occur in up to 15% of patients undergoing UGTI [11]. In our analysis, paresthesia developed in 14.1% of patients, including those at increased risk (i.e. those in need of repeated UGTI). Other complications included venous thrombosis, hematoma, and infection. However, it seems they were related to the psA structure or too late diagnosis, rather than the procedure itself [3, 4, 17, 10].

A new technique for the treatment of pseudoaneurysm

Recently, a new option for the treatment of psA has been proposed [26]. Ultrasound-guided tissue glue injection is a similar technique to UGTI. Its main advantage is simultaneous application of thrombin and fibrinogen, which rapidly generates a stabilized thrombus before the first outflow. As it is a costly method, it should be reserved primarily for patients requiring multiple attempts.

Study limitations

Although we were able to prospectively include a large number of patients, our study is lacking a separate low and high LEVI comparison, and prognostic significance of this measurement. However, the rate of psA recurrence is relatively low, and the number of patients necessary to ensure statistical power could be too small, or the inclusion period could be too long, to obtain reliable results at this time.
In conclusion, the rate of psA recurrence after UGTI was approximately 15%. We propose that the LEVI in spectral Doppler waveform analysis is a novel parameter to select psA patients who may be prone to recurrence. A LEVI of less than 0.2, a time interval between the vessel cannulation and a psA diagnosis longer than 7 days, a psA volume exceeding 5 mL, and a short communicating channel between the psA cavity and the artery, all predicted psA recurrence after UGTI. However, we found that adjunctive pharmacotherapy (i.e. antiplatelet and anticoagulants in different combinations) did not increase the recurrence risk.


The project is supported under the program of the Minister of Science and Higher Education under the name “Regional Initiative of Excellence” in 2019-2022 project number: 024/RID/2018/19, financing amount: 11.999.000,00 PLN.

Conflict of interest

The authors declare no conflict of interest.


1. Maleux G, Hendrickx S, Vaninbroukx J, et al. Precutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysm: short and midterm ultrtasound follow-up. Eur Radiol 2003; 13: 209-12.
2. Ahmed F, Turner S, Torrie P, et al. Iatrogenic femoral artery pseudoaneurysms – a review of current methods of diagnosis and treatment. Clin Radiol 2008; 63: 1310-6.
3. Krueger K, Zaehringer M, Strohe D, et al. Postcatheterization pseudoaneurysm: results of US-guided percutaneous thrombin injection in 240 patients. Radiology 2005; 236: 1104-10.
4. Hofmann I, Wunderlich N, Robertson G, et al. Percutaneous injection of thrombin for the treatment of pseudoaneurysm: the German multicentre registry. EuroIntervention 2007; 3: 321-6.
5. Kruger K, Zahringer M, Sohngen FD, et al. Femoral pseudoaneurysms: management with precutaneous thrombin injections success rate and effects on systemic coagulation. Radiology 2003; 226: 452-8.
6. Calton WC, Franklin DP, Elmore JR, et al. Ultrasound-guided thrombin injection is a safe and durable treatment for femoral pseudoaneurysms. Vasc Surg 2001; 35: 379-83.
7. La Perna L, Olin J, Goines D, et al. Ultrasound-guided thrombin injection for the treatment of postcatheterization pseudoaneurysms. Circulation 2000; 102: 2391-5.
8. Vazquez V, Reus M, Pinero A, et al. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. AJR Am J Roentgenol 2005; 184: 1665-71.
9. Paulson EK, Nelson RC, Mayes CE, et al. Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution AJR Am J Roentgenol 2001; 177: 309-16.
10. Schneider C, Malisius R, Kuchler R, et al. A prospective study on ultrasound-guided percutaneous thrombin injection for treatment of iatrogenic post-catheterisation femoral pseudoaneurysms. Int J Cardiol 2009; 131:356-61.
11. Kurzawski J, Sadowski M, Janion-Sadowska A. Complications of percutaneous thrombin injection in patients with postcatheterization femoral pseudoaneurysm. J Clin Ultrasound 2016; 44: 188-95.
12. Khoury M, Rebecca A, Greene K, et al. Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms. J Vasc Surg 2002; 35: 517-21.
13. Snack T, Bilgic, S Ustuner E. Endovascular stent-graft treatment of a traumatic vertebral artery pseudoaneurysm and vertebrojugular fistula. Korean J Radiol 2008; 9: S68-S72.
14. Thalhammer C, Kirchherr S, Uhlich F, et al. Postcatheterization pseudoaneurysms and arteriovenous fistulas. Repair with percutaneous implantation of endovascular covered stents. Radiology 2000; 214: 127-31.
15. Morgan R, Belli AM. Current treatment methods for post-catheterization pseudoaneurysms. Vasc Interv Radiology 2003; 14: 697-710.
16. Garcia E, Gonzalez-Fajardo JA, Gutierrez V, et al. Femoral pseudoaneurysms post-cardiac catheterization surgically treated: evolution and prognosis. Interact Cardio Vasc Thorac Surg 2009; 8: 353-7.
17. Webber GW, Jang J, Gustavson S, et al. Contemporary management of postcatheterization pseudoaneurysms. Circulation 2007; 115: 2666-74.
18. Hamraoui K, Ernst S, van Dessel P. Efficiency and safety of percutaneous treatment of iatrogenic femoral artery pseudoaneurysm by biodegradable collagen injection. J Am Coll Cardiol 2002; 39:1297-304.
19. Onal B, Ilgit ET, Akpek S, et al. Postcatheterization femoral arteriovenous fistula: endovascular treatment with N-butyl-cyanoacrylate embolization. Cardiovasc Intervent Radiol 2006; 29: 276-8.
20. Matson M, Morgan R, Belli A. Precutaneous treatment of pseudoaneurysm using fibrin adhesive. Br J Radiol 2001; 74: 690-4.
21. Caroll JF, Moskovitz KA, Edward NM. Immunological assessment of patients treated with bovine fibrinogen as a hemostatic agent. Thromb Haemost 1996; 76: 925-31.
22. Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45: 128-35.
23. Pope M, Johnston KW. Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention. J Vasc Surg 2000; 32: 190-1.
24. Villanueva-Benito I, Solla-Ruiz I, Rodriguez-Calveiro R, Maciñeiras-Montero JL, Rodriguez-Paz CM, Ortiz-Saez A. Iatrogenic subclavian artery pseudoaneurysm complicating a transradial percutaneous coronary intervention. JACC Cardiovasc Interv 2012; 5: 360-1.
25. Walker TG, Geller SC, Brewster DC. Transcatheter occlusion of a profunda femoral artery pseudoaneurysm using thrombin. Am J Roentgenol 1987; 149: 185-6.
26. Kurzawski J, Janion-Sadowska A, Sadowski M. A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm. Br J Radiol 2018; 91: 20170538.
Copyright: © 2019 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe